STOCK TITAN

CORCEPT THERAPEUTICS (CORT) SEC Filings, Sep-Oct 2026

CORT NASDAQ

Corcept Therapeutics filings document the regulatory record of a commercial-stage pharmaceutical company focused on cortisol modulation. Recent Form 8-K reports cover operating results, Regulation FD corporate updates, FDA approval of Lifyorli, clinical-trial disclosures for relacorilant programs, patent-dispute developments involving Korlym and material distribution arrangements for Korlym and authorized generic mifepristone.

The company’s proxy materials describe board matters, executive compensation, equity awards and shareholder voting items. Its SEC record also identifies CORT common stock listed on Nasdaq and provides formal disclosures on governance, capital structure, business risks, product regulation, intellectual property and commercialization matters.

Rhea-AI Summary

Corcept Therapeutics (CORT) officer Sean Maduck reported option exercises and common-stock sales on October 1 and October 2, 2026; remarks identify him as President, Corcept Endocrinology. He exercised options for 413 shares on October 1 and 24,587 shares on October 2, each at $8.27 per share, and sold 413 shares at a weighted-average $115.5373 per share on October 1. On October 2, he sold 15,843 shares at a weighted-average $116.1233 and 8,744 shares at $116.5534 per share. The sales were made under a Rule 10b5-1 plan adopted December 8, 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.02%
Tags
insider
-
Rhea-AI Summary

Corcept Therapeutics Inc. officer Justin Frederick Gunn, identified as President, Corcept Endocrinology, acquired a direct award of stock options covering 100,000 shares of common stock on October 1, 2026. The options have an exercise price of $114.025 per share and expire October 1, 2036. They become exercisable ratably in equal installments on each monthly anniversary over four years, subject to his continued service through each vesting date.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.02%
Tags
insider
-
Rhea-AI Summary

Corcept Therapeutics Inc. reports that President, Corcept Endocrinology Justin Frederick Gunn directly holds 12,191 common shares, including shares underlying unvested restricted stock awards and units. It also lists four direct stock-option positions: 25,000 shares at a $37.9400 exercise price, expiring August 1, 2034; 25,000 at $60.5800, expiring February 28, 2035; and 13,438 and 8,959 at $35.7000, both expiring February 27, 2036. Award vesting is subject to stated requirements, and option vesting is subject to continued service.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.02%
Tags
insider
Rhea-AI Summary

Corcept Therapeutics (CORT) officer Joseph D. Lyon reported a proposed sale of 10,000 common shares, with an aggregate market value of $1,152,300.00, on October 1, 2026, through Stifel Nicolaus. The shares are listed as acquired from the issuer through a stock option exercise for cash. Earlier reported sales were 1,540 shares for $175,725.77 on August 3, 2026, and 10,000 shares for $1,134,423.74 on September 14, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.05%
Tags
other
-
Rhea-AI Summary

Corcept Therapeutics Inc. Chief Business Officer Gary Charles Robb reported giving 17,100 common shares on September 24, 2026, leaving 14,056 shares held directly; that balance includes shares underlying unvested restricted stock awards. On the same date, two separate transactions of 5,000 shares each were reported as acquisitions in custodial accounts under the Uniform Transfers to Minors Act. Robb was trustee of a revocable trust holding 39,716 shares indirectly.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.77%
Tags
insider
-
Rhea-AI Summary

Corcept Therapeutics Incorporated (CORT) announced that Sean Maduck, President of its Endocrinology division, will retire effective October 1, 2026, and that Justin Gunn will succeed him and fully assume the role that day. Gunn will join the Executive Team and report to Chief Executive Officer Joseph K. Belanoff.

Maduck will provide consulting services to the CEO and executive management under an agreement effective October 1, 2026, with an initial term through September 30, 2027, unless terminated earlier. His cash fee is $57,000 per month, and his previously awarded, outstanding stock options will continue vesting on their original schedules during the consulting term. Either party may terminate with 30 days’ prior written notice. The company stated his resignation was not due to disagreement over its operations, financial statements, policies or practices.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.88%
Tags
current report
Rhea-AI Summary

CORCEPT THERAPEUTICS INC (CORT) reported that Roberto Wandenkolk Vieira, President, Oncology, sold 296 shares of common stock on September 16, 2026 at $100.82 per share in an open-market transaction under a Rule 10b5-1 trading plan. After the sale, he held 3,946 shares directly, including 1,347 unvested restricted stock award shares scheduled to vest in full on the one-year anniversary of each grant date subject to conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.15%
Tags
insider
-
Rhea-AI Summary

Corcept Therapeutics Inc. (CORT) reports that Chief Business Officer Gary Charles Robb exercised options for 17,493 shares of common stock on September 17, 2026 at an exercise price of $8.27 per share, converting a fully exercisable option into common shares. Following this transaction, he holds 31,156 common shares directly, including 1,663 shares underlying unvested restricted stock awards that vest on the one-year anniversaries of their grant dates if conditions are met, and continues to hold 182,507 options directly that expire on February 10, 2027. He also has indirect ownership of 39,716 common shares through a revocable trust for which he is trustee, plus additional indirect holdings in custodial accounts for his children, and no Rule 10b5-1 trading plan is reported.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.15%
Tags
insider
-
Rhea-AI Summary

CORCEPT THERAPEUTICS INC (CORT) reported that its Chief Accounting & Technology Officer, Joseph Douglas Lyon, exercised stock options for a total of 10,000 shares of common stock on September 14, 2026, at exercise prices of $11.35 and $13.56 per share, and sold 10,000 shares the same day in open-market or private transactions under a Rule 10b5-1 trading plan.

The sales were executed in two tranches at weighted average prices of $113.32 and $114.12 per share, and the filing notes that Lyon also holds unvested restricted stock awards scheduled to vest one year after their respective grant dates, subject to specified service conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.73%
Tags
insider
Rhea-AI Summary

CORCEPT THERAPEUTICS INC (CORT) director James N. Wilson reported indirect sales of a total of 10,000 shares of common stock on September 15, 2026 by the James N. Wilson and Pamela D. Wilson Trust. The shares were sold in open-market transactions under a Rule 10b5-1 trading plan adopted on March 12, 2026, at weighted average prices between $109.66 and $111.705 per share. Wilson has voting power over the trust’s shares under voting agreements and disclaims beneficial ownership except to the extent of his pecuniary interest. The filing also reports indirect holdings of 200,000 shares each in the James N. Wilson 2025 Grantor Retained Annuity Trust and the Pamela D. Wilson 2025 Grantor Retained Annuity Trust as of September 15, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.73%
Tags
insider

FAQ

How many CORCEPT THERAPEUTICS (CORT) SEC filings are available on StockTitan?

StockTitan tracks 201 SEC filings for CORCEPT THERAPEUTICS (CORT), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for CORCEPT THERAPEUTICS (CORT)?

The most recent SEC filing for CORCEPT THERAPEUTICS (CORT) was filed on November 13, 2026.